Lead Product(s) : Stenoparib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Allarity’s Stenoparib Continues to Show Benefit in Advanced Ovarian Cancer
Details : 2X-121 (stenoparib) is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. It is being evaluated for the treatment of advanced recurrent ovarian cancer.
Brand Name : 2X-121
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 25, 2024
Lead Product(s) : Stenoparib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Stenoparib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Allarity’s Stenoparib Shows Clear Benefit with Early Conclusion of Phase 2 Trial
Details : 2X-121 (stenoparib) is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. It is being evaluated for the treatment of advanced recurrent ovarian cancer.
Brand Name : 2X-121
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 02, 2024
Lead Product(s) : Stenoparib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Stenoparib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Allarity Shifts Focus to Accelerating Stenoparib Toward Approval in Ovarian Cancer
Details : 2X-121 (stenoparib) is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. It is being evaluated for the treatment of advanced recurrent ovarian cancer.
Brand Name : 2X-121
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 27, 2024
Lead Product(s) : Stenoparib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Stenoparib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : 2X-121 (stenoparib) is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. It is being evaluated for the treatment of advanced recurrent ovarian cancer.
Brand Name : 2X-121
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2023
Lead Product(s) : Stenoparib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Stenoparib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : 2X-121 (stenoparib) is a PARP inhibitor in Phase 2 development for ovarian cancer and in Phase 1 development for advanced solid tumors in a combination treatment with dovitinib, a pan-tyrosine kinase inhibitor that has previously been developed through P...
Brand Name : 2X-121
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 28, 2023
Lead Product(s) : Stenoparib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dovitinib,Stenoparib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Stenoparib is a dual-targeted inhibitor of PARP 1, 2 and tankyrase 1, 2 where dovitinib is a pan-tyrosine kinase inhibitor. The combination may increase the chances of cancer apoptosis and providing synergistic, enhanced antitumor activity.
Brand Name : TKI258
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 20, 2023
Lead Product(s) : Dovitinib,Stenoparib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dovitinib,Stenoparib
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies
Details : The DRP® platform has proven its ability to provide a statistically significant prediction of clinical outcome from drug treatment in cancer patients in 37 out of 47 clinical studies that were examined including ongoing, prospective Phase 2 trials of St...
Brand Name : TKI258
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 02, 2022
Lead Product(s) : Dovitinib,Stenoparib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Stenoparib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Viroclinics Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The additional pre-clinical results show that stenoparib demonstrated antiviral activity inhibiting the delta variant in a dose-dependent manner in Vero E6 cells. The delta variant used for the experiments carries an additional deletion in ORF7a, a rapid...
Brand Name : 2X-121
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 11, 2021
Lead Product(s) : Stenoparib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Viroclinics Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Stenoparib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Currently, the delta variant (lineage B.1.617.2) has become the dominant strain of SARS-CoV-2, and near-term tests of stenoparib against this variant are being initiated by Allarity.
Brand Name : 2X-121
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 05, 2021
Lead Product(s) : Stenoparib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Stenoparib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The current and planned in-vitro studies, focusing on SARS-CoV-2 lineage B.1.1.7 and B.1.351, follow previous positive pre-clinical test results with stenoparib as a treatment of SARS-CoV-2 published in the peer-review journal mBio.
Brand Name : 2X-121
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 24, 2021
Lead Product(s) : Stenoparib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?